Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 6/2019

01-06-2019 | Interventional

Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques

Authors: Shamar Young, Paul Craig, Jafar Golzarian

Published in: European Radiology | Issue 6/2019

Login to get access

Abstract

Purpose

Despite being accepted as a mainstay of treatment for hepatocellular carcinoma (HCC), technical aspects of transarterial chemoembolization (TACE) continue to vary by reporting author, leading to heterogeneity in the literature and making meaningful comparisons between treatments difficult. The goal of this survey was to report international chemoembolization practices for the treatment of HCC in an effort to understand current treatment strategies as a first step towards technique standardization.

Materials and methods

An anonymous 18-question online survey, evaluating technical aspects of their TACE practice, was distributed via email to practicing members of the five largest interventional radiology societies in Chinese and English. A total of 1160 responses were obtained from 62 countries. Responses were categorized according to region of practice and analyzed using Fisher’s exact test and chi-square test with Bonferroni correction as needed.

Results

There were significant statistical differences between regions for nearly all questions. Doxorubicin was more commonly used among respondents from North America, Europe, and South Korea than Japan and China (p = 0.0001). For single and multiple HCCs, drug-eluting bead TACE was most popular in North America and Europe (p = 0.0001), while conventional TACE was most popular in Japan, Korea, and China (p = 0.0001). CT was the most commonly used modality for follow-up among all respondents, although MR was used more commonly in North America and in academic centers (p = 0.0001).

Conclusion

This survey provides comprehensive information on and confirms the heterogeneous nature of current practice patterns in regard to TA(C)E for HCC.

Key Points

• There is a lack of information regarding current practice patterns in the area of technical considerations when performing transarterial chemoembolization.
• Type of transarterial chemoembolization utilized to treat hepatocellular carcinoma varies widely across geographical area.
• Chemotherapeutic agents and embolic agents used to perform transarterial chemoembolization for the treatment of hepatocellular carcinoma vary widely across geographical areas.
Appendix
Available only for authorised users
Literature
1.
Forner A, Gilabert M, Bruix J, Raoul JL (2014) Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 11:525–535CrossRefPubMed
2.
3.
European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
4.
Llovet JM, Real MI, Montaña X et al (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739CrossRefPubMed
5.
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171CrossRefPubMed
6.
Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590CrossRefPubMed
7.
Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33:41–52CrossRef
8.
Brown KT, Do RK, Gonen M et al (2016) Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. J Clin Oncol 34:2046–2053CrossRefPubMedPubMedCentral
9.
Gaba RC (2012) Chemoembolization practice patterns and technical methods among interventional radiologists: results of an online survey. AJR Am J Roentgenol 198:692–699CrossRefPubMed
10.
Bargellini I, Florio F, Golfieri R, Grosso M, Lauretti DL, Cioni R (2014) Trends in utilization of transarterial treatments for hepatocellular carcinoma: results of a survey by the Italian Society of Interventional Radiology. Cardiovasc Intervent Radiol 37:438–444CrossRefPubMed
11.
Gaba RC, Baerlocher MO, Nikolic B, Venkatesan AM, Lewandowski RJ (2015) Clinical and imaging follow-up practices after transarterial therapy for primary and secondary hepatic malignancies: results of an online survey. Acad Radiol 22:1510–1515CrossRefPubMed
12.
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefPubMed
13.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMed
14.
Favoulet P, Cercueil JP, Faure P et al (2001) Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 12:801–806CrossRefPubMed
15.
Marelli L, Sigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25CrossRefPubMed
16.
Sahara S, Kawai N, Sato M et al (2012) Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anticancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 35:1363–1371CrossRefPubMed
17.
Tawanda A, Chiba T, Ooka Y et al (2015) Transarterial chemoembolization with miriplatin plus epirubicin in patients with hepatocellular carcinoma. Anticancer Res 35:549–554
18.
Liu B, Huang JW, Li Y et al (2015) Single-agent versus combination doxorubicin-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a single-blind, randomized, phase II trial. Oncology 89:23–30CrossRefPubMed
19.
Shi M, Lu LG, Fang WQ et al (2013) Roles played by chemolipodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst 105:59–68CrossRefPubMed
20.
Jordan O, Denys A, De Baere T, Boulens N, Doelker E (2010) Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 21:1084–1090CrossRefPubMed
21.
Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335–342CrossRefPubMed
22.
Matsui O, Kadoya M, Yoshikawa J et al (1993) Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology 188:79–83CrossRefPubMed
23.
Matsuo N, Uchida H, Nishimine K et al (1993) Segmental transcatheter hepatic artery chemoembolization with iodized oil for hepatocellular carcinoma: antitumor effect and influence on normal tissue. J Vasc Interv Radiol 4:543–549CrossRefPubMed
24.
Nakamura H, Tanaka T, Hori S et al (1983) Transcatheter embolization of hepatocellular carcinoma: assessment of efficacy in cases of resection following embolization. Radiology 147:401–405CrossRefPubMed
25.
Gao S, Yang Z, Zheng Z et al (2013) Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 60:813–820PubMed
26.
Facciorusso A, Di Maso M, Muscatiello N (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 48:571–577CrossRefPubMed
27.
Zou JH, Zhang L, Ren ZG, Ye SL (2016) Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis 17(8):510–517CrossRefPubMed
28.
Golfieri R, Giampalma E, Renzulli M et al (2014) Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolization for hepatocellular carcinoma. Br J Cancer 111:255–264CrossRefPubMedPubMedCentral
29.
Sacco R, Bargellini I, Bertini M et al (2011) Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 22:1545–1552CrossRefPubMed
30.
Van Malenstein H, Maleux G, Vandecaveye V et al (2011) A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie 34:368–376CrossRefPubMed
Metadata
Title
Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques
Authors
Shamar Young
Paul Craig
Jafar Golzarian
Publication date
01-06-2019
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 6/2019
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5782-7

Other articles of this Issue 6/2019

European Radiology 6/2019 Go to the issue

Correction

Correction to: Ultrashort time-to-echo quantitative magnetic resonance imaging of the triangular fibrocartilage: differences in position

Forensic Medicine

A systematic review of the agreement between chronological age and skeletal age based on the Greulich and Pyle atlas

Breast

Pre- and post-contrast versus post-contrast cone-beam breast CT: can we reduce radiation exposure while maintaining diagnostic accuracy?

Gastrointestinal

Symptom relief and not cyst reduction determines treatment success in aspiration sclerotherapy of hepatic cysts

Cardiac

Additional diagnostic value of new CT imaging techniques for the functional assessment of coronary artery disease: a meta-analysis

Chest

Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer